Hanover Portfolio Acquisitions, Inc. cancelled the acquisition of 70% stake in Pulsed Energy Technologies, LLC.
January 07, 2014 at 11:00 pm EST
Share
Hanover Portfolio Acquisitions, Inc. executed a letter of intent to acquire 70% stake in Pulsed Energy Technologies, LLC on January 8, 2013. As a part of the transaction, Hanover Portfolio will acquire all of the intellectual property, assets, and accounts receivables of Pulsed Energy Technologies. The transaction is expected to be accretive to Hanover Portfolio shareholders through immediate revenue generation. Andrew Haag of Hampton Growth acted as investor relations advisor.
Hanover Portfolio Acquisitions, Inc. cancelled the acquisition of 70% stake in Pulsed Energy Technologies, LLC on January 8, 2014.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
ENDONOVO THERAPEUTICS, INC. 